WHO Executive Board meeting discusses consensus on R&D for neglected diseases

NewsGuard 100/100 Score

Intellectual Property Watch reports on discussions at the ongoing WHO Executive Board meeting "over legal and political aspects of a consensus reached by a small number of member states in November on implementing a plan to address the global lack of research and development [R&D] for neglected diseases predominantly afflicting poor populations." The news service writes, "A top issue for the week is the longstanding public health policy problem of finding ways to stimulate R&D on treatments for diseases for which there is little incentive for the private sector to invest, since they traditionally recoup their R&D costs through high prices on the resulting medicines." IP Watch describes the outcomes of a November 2012 meeting to discuss the issue, writing, "This compromise outcome disappointed a number of member states and public health advocates who have been working on this issue at WHO for many years leading up to this point and hoped for a more ambitious plan." The news service describes the ongoing debate (New, 1/28).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings